tbuckley/cabot-search huggingface dataset:
SP0032 The Race for Imaging Biomarkers
Authors: P. Mandl
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> Imaging tools may help diagnose, monitor and treat diseases earlier. Imaging biomarkers have unique advantages and limitations compared to other biomarkers. They provide information on the exact site of the disease, are relatively non-invasive and allow follow-up. However unlike biospecimens or physiological measurements, the quality and validity of imaging measurements as biomarkers commonly depends on the use and technical characteristics of the diagnostic imaging device, and in some cases also on the expertise of the operator as well. Moreover, for many imaging biomarkers, standardisation of acquisition and analysis as well the identification of objectively measured characteristics poses additional concerns. Nonetheless imaging biomarkers have the potential to detect and monitor rheumatic diseases as well as predict response to treatment. In order to qualify, an imaging biomarker has to be accurate, reproducible, standardized and suitable for multicenter evaluation and needs to demonstrate correlation with either anatomy/pathology or with other imaging modalities. Furthermore, in order to be used as a predictive biomarker, it needs to be closely linked to the success or failure of the therapeutic effect and with the clinical outcome relevant to the disease. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6322
Rapid Transit of Tracer to the Kidneys and Urinary Bladder in Radionuclide Cisternography
Authors: RAGHUREER HALKAR, RODERIC PETTIGREW, CRAIG LIPMAN, LYNN GILLES
Journal: Clinical Nuclear Medicine (1997)

A 20-year-old woman complained of postural headache after severe emesis. Lumbar puncture showed no abnormality except for low cerebrospinal fluid pressure. Radionuclide cisternography at 4-hour and 24-hours showed no tracer in the basal cisterns or cerebral convexities. The 4-hour image showed tracer in the renal area, and at 24 hours there was tracer in the urinary bladder. There was no direct evidence of CSF leak. A CT myelogram showed a CSF leak near the third and fourth lumbar nerve roots.
Substantial slice of £4.2bn IT fund must go to general practice, say GP leaders
Authors: Adrian O’Dowd
Journal: BMJ (2016)

Almost half a billion pounds of the government’s £4.2bn (€5.3bn; $6bn) IT infrastructure fund should be allocated to general practice for the money to be used most effectively for better patient care, GP leaders have said.

Maureen Baker, chair of the Royal College of General Practitioners, has written to England’s health secretary, Jeremy Hunt, to welcome his announcement in February of £4.2bn to create a “paperless NHS,” but she has called for a significant proportion of the money to go to general practice.

Hunt announced that the …
1183 IN VIVO ANTIGENIC TARGETS OF T CELLS INDUCED BY ADENOVIRAL VECTORED VACCINES IN PATIENTS WITH CHRONIC HCV INFECTION
Authors: C. Kelly, A. Folgori, S. Capone, A.C. Brown, L. Swadling, R. Townsend, J. Halliday, E. Stafford, D. O'Donnell, M. Naddeo, J. Collier, D. Adams, S. Colloca, C. Traboni, R. Cortese, A. Nicosia, P. Klenerman, E. Barnes
Journal: Journal of Hepatology (2012)
SAT0027 Targeted Treatment and Combination Dmard Therapy are Additively Important for Maintaining Work Ability in Early Rheumatoid Arthritis
Authors: V. Rantalaiho, H. Kautiainen, T. Möttönen, K. Puolakka
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Early remission is the key for preventing work disability (WD) in rheumatoid arthritis (RA) [1]. Monitoring disease activity and targeting remission, as well as using initial combinations of disease modifying antirheumatic drugs (DMARDs) are the best ways to reach early remission. <h3>Objectives</h3> To study separately the roles of targeted treatment and combination therapy in the prevention of WD days during 5 years after the diagnosis of RA. <h3>Methods</h3> In the FIN-RACo trial, 162 patients, working or available to work, with early, active RA were randomized to be treated for 2 years either with a triple-combination of DMARDs and prednisolone (PRD) (FIN-RACo), or with DMARD monotherapy and discretionary PRD (SINGLE); after 2 years the treatments became unrestricted [2]. Throughout the follow-up the treatment was aimed at strict ACR remission so that in continuous disease activity all inflamed joints were to be injected with glucocorticoids and predefined treatment adjustments to be made. However, further analyses have shown heterogeneity in the activity of the participating physicians. Here we divided them into active (ACT) and non-active (non-ACT) as per their fidelity to following the protocol. According to the original randomization group and the physician’s activity, we then formed 4 groups of patients: 1 FIN-RACo+ACT, 2 FIN-RACo+non-ACT, 3 SINGLE+ACT, and 4 SINGLE+non-ACT and analysed the cumulative WD days up to 5 years in these sub-groups. <h3>Results</h3> The cumulative WD days in different groups throughout the 5-year follow-up are presented in Figure. Their numbers by groups were as follows: 1: 222; 2: 470; 3: 491; 4: 650 (age, sex adjusted p&lt;0.001). <h3>Image/graph</h3> <h3>Conclusions</h3> In early RA, targeted treatment and combination-DMARD therapy are equally and additively important for preventing WD. <h3>References</h3> Puolakka et al. Arthritis and rheumatism. 2005;52:36-41. Möttönen et al. Lancet. 1999;353:1568-73. <h3>Disclosure of Interest</h3> None Declared
Overexpression of the MDR1 Gene and P-Glycoprotein in Human Hepatocellular Carcinoma
Authors: C. Huang, M. Wu, G. Xu, D. Li, H. Cheng, Z. Tu, H. Jiang, J. Gu
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Overexpression of the MDR1 Gene and P-Glycoprotein in Human Hepatocellular Carcinoma Get access Chengcheng Huang, Chengcheng Huang Institute of Hepatobiliary Surgery, Shanghai HospitalShanghai, People's Republic of China Search for other works by this author on: Oxford Academic PubMed Google Scholar Mengchao Wu, Mengchao Wu Institute of Hepatobiliary Surgery, Shanghai HospitalShanghai, People's Republic of China Search for other works by this author on: Oxford Academic PubMed Google Scholar Gouwei Xu, Gouwei Xu National Laboratory for Oncogenes, Shanghai Cancer InstituteShanghai Search for other works by this author on: Oxford Academic PubMed Google Scholar Daizhong Li, Daizhong Li National Laboratory for Oncogenes, Shanghai Cancer InstituteShanghai Search for other works by this author on: Oxford Academic PubMed Google Scholar Han Cheng, Han Cheng Institute of Hepatobiliary Surgery, Shanghai HospitalShanghai, People's Republic of China Search for other works by this author on: Oxford Academic PubMed Google Scholar Zhengxing Tu, Zhengxing Tu Institute of Hepatobiliary Surgery, Shanghai HospitalShanghai, People's Republic of China Search for other works by this author on: Oxford Academic PubMed Google Scholar Huiqiu Jiang, Huiqiu Jiang National Laboratory for Oncogenes, Shanghai Cancer InstituteShanghai Search for other works by this author on: Oxford Academic PubMed Google Scholar Jianren Gu Jianren Gu National Laboratory for Oncogenes, Shanghai Cancer InstituteShanghai Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 4, 19 February 1992, Pages 262–264, https://doi.org/10.1093/jnci/84.4.262 Published: 19 February 1992 Article history Received: 28 August 1991 Revision received: 04 November 1991 Accepted: 22 November 1991 Published: 19 February 1992
Health gap between Aboriginal and non-Aboriginals widening
Authors: C. Zinn
Journal: BMJ (1997)

A damning report has revealed a widening gap between the health of Aboriginal and non-Aboriginal people.

The most comprehensive survey ever on the subject shows that Aborigines are six to eight times more likely to die aged 25 to 55 years than white Australians. They have a life expectancy matched only by places like India and central Africa.

The report, The Health and Welfare …
Postprocedural Blue Toes
Authors: Grant K. Ghahramani, Alison E. Seline, Karolyn A. Wanat
Journal: JAMA (2016)

A man in his 70s with a history of recent CABG surgery presented with blue, tender plantar macules on several toes and red, tender macules on his hands. Laboratory findings included a BUN level of 70 mg/dL, serum creatinine level of 6.1 mg/dL, and peripheral eosinophilia. What would you do next?
AB0893 Presence of Antibodies to Cyclic Citrullinated Peptides in Juvenile-Onset Systemic Lupus Erythematosu
Authors: H. Zeng, H. Liu, Y. Liu, Q. Guan
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To determine the prevalence of antibodies to cyclic citrullinated peptides (anti-CCP) in patients with juvenile-onset systemic lupus erythematosus (JSLE) and its potential clinical significance. <h3>Methods</h3> Anti-CCP was measured in sera from patients with JSLE (n=47), juvenile idiopathic arthritis (JIA, n=54) and the sera from age-matched healthy children (n-40) using the third generation of anti-CCP ELISA commercial kit. The association of anti-CCP with other laboratory parameters and clinical features, especially arthritic symptoms in JSLE was also analyzed. T-test, Mann-Whitney U test, Chi-square and Fisher9s exact test were used for statistical analysis. <h3>Results</h3> Out of the 47 JSLE patients, 6 (13%) were anti-CCP positive,which was significantly higher than that of the healthy controls (13% vs 0, P&lt;0.05), but not difierent from that of the JIA group (26%, P=0.098). RF was more prevalent in JSLE patients with anti-CCP than patients without (83% vs 15%, P&lt;0.01), but there was no difference in other laboratory parameters and the clinical features including the occurrence of arthritis (67% vs 51%, P&gt;0.05). As one of the initial symptoms, arthritis was ohserved in 25 of 47 JSLE patients and no one had developed deforming athropathy. There was no statistical difference in anti-CCP positivity between JSLE patients with and without articular involvement (16% vs 9%, P&gt;0.05). Anti-CCP was not detected in any of the 3 patients with JSLE who had experienced ioint pain and limited activity during 3 years foIlow-up. <h3>Conclusions</h3> Anti-CCP could be detected in patients with JSLE.It is noteworthy when differentiate from juvenile idiopathic arthritis, but the presence of anti-CCP does not relate with the occurrence of arthritis at presentation and persistence of arthritis in JSLE. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5615
Endoscopic removal of biliary self-expandable metallic stents: a prospective study
Authors: H. Shin, M.-H. Kim, S. Jung, J. Kim, E. Choi, J. Han, S. Lee, D. Seo, S. Lee
Journal: Endoscopy (2006)

The transpapillary endoscopic insertion of self-expandable metallic stents (SEMSs) has been widely used for the palliation of unresectable malignant biliary obstruction. We attempted the endoscopic removal of malfunctioning SEMSs. The aim of this study was to assess the feasibility and safety of the endoscopic removal of SEMSs by comparing the results between removal of covered and uncovered SEMSs.30 patients with a malfunctioning biliary SEMS prospectively underwent an attempt at endoscopic removal of the biliary SEMS over a 2-year period. Removal of the malfunctioning SEMS was done with a therapeutic duodenoscope (ED-450XT5 or TJF-240), using a rat-tooth forceps. Of the 30 SEMS used, 22 were silicone-covered Wallstents, while eight were uncovered SEMSs including five uncovered Wallstents and three Zilver stents. The time for an attempt at each endoscopic removal was limited to 15 minutes in a single endoscopic procedure session.The covered SEMSs were easily removed in 19 out of 22 patients (86.4 %), whereas none of the eight uncovered SEMSs (0 %) could be removed. The only factor predicting successful stent removal was the presence of a stent covering ( P = 0.000). There was no morbidity or mortality related to endoscopic removal of malfunctioning stents.In contrast to uncovered biliary SEMSs, in most cases malfunctioning covered biliary SEMSs can be easily and safely removed endoscopically using a rat-tooth forceps.
Abstract 5005: Large-scale DNA methylation profiling in gastrointestinal stromal tumors (GIST) reveals epigenetic regulation of SPP1 as an independent prognostic factor
Authors: Florian Haller, Jitao David Zhang, Yasser Riazalhosseini, Aoife Ward, Aleksandra Balwierz, Bernhard Korn, Inga-Marie Schaefer, Silke Cameron, B. Michael Ghadimi, Abbas Agaimy, Jonathan A. Fletcher, Jörg Hoheisel, Stefan Wiemann, Özgür Sahin
Journal: Cancer Research (2012)

Abstract Aims Gastrointestinal stromal tumors (GISTs) have distinct gene expression patterns according to anatomical localisation and genotype, with potential impact on biological aggressiveness. DNA methylation of CpG dinucleotides in the promoter region of genes is an important mechanism for regulation of gene expression. We performed a large-scale analysis of DNA methylation in GISTs to identify methylation patterns associated with clinico-pathological parameters and prognosis. Methods Seventy-five GISTs with either KIT or PDGFRA mutations were analysed for DNA methylation of 1.505 CpG sites in the promoter regions of 807 cancer-related genes using a large-scale approach (Cancer Methylation Panel I, Illumina). Epigenetic regulation of Secreted Phosphoprotein 1 (SPP1) expression was analysed at mRNA and protein levels in GIST882 and GIST48b cells after treatment with a demethylating agent. Impacts on tumorigenesis-related signalling pathways were analysed by Western Blot after stimulation of GIST cell lines with SPP1. Prognostic impact of SPP1 at methylation and protein levels were investigated in 75 and 121 GIST tumor samples, respectively, and compared to classical prognostic parameters tumor size, mitotic counts and tumor localisation. Results Principal component analysis revealed distinct DNA methylation patterns according to anatomical localisation, genotype and mitotic counts. Hypomethylation of a CpG dinucleotide 647 base pairs upstream of the transcription start site of SPP1 was significantly correlated to SPP1 mRNA and protein level, and also to tumor progression (p=0.003). In vitro analyses confirmed epigenetic regulation of SPP1 expression, and demonstrated potential impact on proliferation and invasion. High protein level of SPP1 was significantly correlated to shorter disease-free survival in univariate (p=2x10−7) and multivariate (p&amp;lt;1x10−6) analyses. Conclusion The expression of SPP1 is regulated epigenetically in GISTs, and high expression of SPP1 is a novel and independent prognostic parameter in GISTs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5005. doi:1538-7445.AM2012-5005
EXPERIENCE TREATING IN-STENT RESTENOSIS LESIONS FROM A MULTICENTER REGISTRY
Authors: Subhash Banerjee, Karan Sarode, Atif Mohammad, Osvaldo Gigliotti, Michael Luna, Tayo Addo, Mirza Baig, Shirling Tsai, Nicolas Shammas, Anand Prasad, Mazen Abu-Fadel, Andrew Klein, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2015)
Reply to Linghu
Authors: A. Fritscher-Ravens
Journal: Endoscopy (2012)

We read with great interest the letter by Yang and Linghu, which discussed the proof of diagnosis for tuberculosis and sarcoidosis in our study of patients in whom routine diagnostic procedures had failed. For the diagnosis of tuberculosis we chose an unconventional “gold standard,” which was drawn from the UK National Institute for Health and Clinical excellence (NICE) guidelines, to confirm or refute the diagnosis of tuberculosis by the composite end-point of culture, radiographic appearances (i. e. repeated computed tomography scan), repeated endoscopic ultrasonography-guided fine-needle aspiration where thought to be necessary, and clinical deterioration as determined over a 12-month follow-up period [1].
Abstract 3888: Ionizing radiation destabilizes inverted ALU repeats linked to LOH
Authors: Bay Ho, Sheetal Singh, Shyh-Jen Shih, Pamela M. Baker, To Uyen Do, Andrew T.M Vaughan
Journal: Cancer Research (2011)

Abstract Ionizing radiation is a potent inducer of Loss of Heterozygosity (LOH), driven primarily by DNA double strand breaks. Such a process impacts both tumorigenesis through deletion of linked tumor suppressor genes and, similarly, the potential development of radiation resistant tumor clones during radiation therapy. The human mucoepidermoid cell line, H292, was exposed to either 4 or 8 Gy and surviving clones developed from two rounds of cloning analyzed for LOH using polymorphic microsatellite markers. A high level of LOH was observed within individual clones extending from 11q21 to 11q24 (6/49 after 4 Gy and 8/50 after 8Gy). More detailed analysis using a SNP screen on selected LOH positive clones indicated a sharp telomeric termination of LOH adjacent to a common SNP location. The telomeric extent of LOH observed co-mapped to a region of elevated recombination instability documented previously using linkage analysis. Further, SNP analysis showed a region of approximately 1 Mbp LOH that included the region of recombination instability identified through linkage analysis, in some clones isolated either with or without irradiation. The consistency of the telomeric boundary of LOH observed in the irradiated clones permitted a targeted analysis of DNA double strand breaks at this location, using LM-PCR, both before and after 4Gy irradiation of the same cell line. Using a six primer set screen covering a 9 kbp region at the telomeric extent of radiation-induced LOH, a single primer set showed an elevation in DNA breaks from 2-8h after irradiation. The timing and discrete distribution of such breaks indicated that these were not directly induced by the radiation itself. Cells that were unirradiated were not affected. Further inspection of the location demonstrating selective radiation-linked fragmentation showed the presence of an ALU inverted repeat, separated by approximately 1kbp, where the DNA breaks determined by LM-PCR were clustered within the 5’ ALU. Others have shown previously that inverted ALU repeats separated by &amp;lt;20bp are recombinationally unstable and are underrepresented within the human genome. It is proposed that, within the H292 cell line, otherwise stable ALU inverted repeats are capable of forming a transient hairpin conformation, perhaps facilitated by their own transcription via RNA polymerase III, which is unstable within a genome undergoing DNA damage and repair. The combination of such inverted ALU repeats and genotoxic exposure, such as during radiation therapy, may therefore destabilize specific regions of the genome and contribute to the development of aberrant cell clones. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3888. doi:10.1158/1538-7445.AM2011-3888
P12.06 * INTRAVENTRICULAR BRAIN TUMORS: PECULIARITIES OF SURGICAL TREATMENT
Authors: T. Havryliv, V. Smolanka
Journal: Neuro-Oncology (2014)

INTRODUCTION: Intraventricular brain tumors account for approximately 10% of all tumors of the central nervous system. Despite the fact that some of these tumors are aggressive high grade lesions, most of them are histologically benign and potentially curable after surgical resection. Considering the slow growth of this tumors, for a long time this lesions remain clinically asymptomatic, until they reach significant size, which makes surgical removal technically difficult. The aim of the current study was to identify patterns of results of surgical treatment of patients with intraventricular tumors, depending on the lesion location and its degree of differentiation. MATERIAL AND METHODS: A retrospective analysis of 54 consecutive surgical interventions on intraventricular brain tumors that were treated at the Uzhhorod Regional Clinical Center of Neurosurgery and Neurology in the period from January 2004 to February 2014. Localization of tumors was as follows: the fourth ventricle - 32 (59%), third ventricle - 13 (24%), lateral ventricles - 9 (17%). Neurological symptoms due to increased intracranial pressure was a common clinical manifestation of tumors for all patients. We used the following surgical approaches: suboccipital craniotomy for tumors of the fourth ventricle, transcallosal or transcortical-transventricular approach to the third ventricle and transcortical approach to lesions of lateral ventricles. Histological structure of the tumors: ependymoma - 13 (24%), astrocytoma - 12 (22%), medulloblastoma - 8 (14.0%), colloid cyst - 7 (13.0%), choroid plexus papilloma - 6 (11%), meningioma - 3 (6%), choroid plexus carcinoma - 1 (2%), teratoma - 1 (2%), central neurocytoma - 1 (2%), dermoid cyst - 1 (2%), chordoid glioma of the third ventricle - 1 (2%). The degree of tumors differentiation: grade I-II - 37 (69%), grade III-IV - 17 (31%). RESULTS: According to the data, among intraventricular tumors prevail the tumors of the fourth ventricle (59%), the most frequent histological type - ependymoma (24%). The total tumor removal was achieved in 38 patients (70%), of whom in 33 (87%) the degree of tumor differentiation was grade I-II. Postoperative mortality was 9% (5 patients), of which 4 (80%) - with the localization of the tumor in the third and fourth ventricles. The results of treatment were assessed according to Karnofsky scale: more than 60 points - 46 (85%) patients. CONCLUSIONS Acceptable results of surgical treatment of intraventricular brain tumours are in direct dependence from the tumor localisation and its histological structure. The most unfavorable factor is the localization of tumors in close proximity to the brainstem and the low degree of tumor differentiation.
DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis
Authors: Petro Starokadomskyy, Terry Gemelli, Jonathan J Rios, Chao Xing, Richard C Wang, Haiying Li, Vladislav Pokatayev, Igor Dozmorov, Shaheen Khan, Naoteru Miyata, Guadalupe Fraile, Prithvi Raj, Zhe Xu, Zigang Xu, Lin Ma, Zhimiao Lin, Huijun Wang, Yong Yang, Dan Ben-Amitai, Naama Orenstein, Huda Mussaffi, Eulalia Baselga, Gianluca Tadini, Eyal Grunebaum, Adrijan Sarajlija, Konrad Krzewski, Edward K Wakeland, Nan Yan, Maria Teresa de la Morena, Andrew R Zinn, Ezra Burstein
Journal: Nature Immunology (2016)
Construction and Validation of a Health-Related Quality of Life (HR-QOL) Instrument for Patients with Primary Antibody Deficiency Disease
Authors: Mark Ballow, Mark R. Conaway, Rima A. Rachid, Filiz O. Seeborg, Panida Sriaroon, Carla M. Duff, M. Elizabeth M. Younger, Ralph Shapiro, Ted M. Burns
Journal: Journal of Allergy and Clinical Immunology (2016)